New lines of attack and advances and for improved anti-angiogenesis and vascular targeting cancer therapeutics

Research and Markets have announced the addition of the following New Lines of Attack in Cancer Anti-Angiogenesis Report to their offering

Development of an adequate blood supply is one of the essential factors that dictate malignant growth and cancer development. An extensive number of companies seek to affect tumor growth by targeting angiogenesis and neovascularisation via techniques aimed at inhibiting new blood vessel growth or destroying already existing tumor vasculature. Despite early enthusiasm for angiogenesis inhibitors as safe and effective anticancer drugs, results of several completed Phase III and Phase II trials have been disappointing. New stratagies have been developed to overcome these previous mistakes.
Since the early failure of drugs such as Avastin, Erbitux, SU5416, Marimastat, Endostatin and Angiostatin, new clinical trials have commenced that will define whether the anti-angiogenetic strategy will hold.

The American Cancer Society estimates that approximately 1.2 million new cancer cases are diagnosed each year in the US. According to International Union Against Cancer (IUAC), approximately $164 billion is spent globally on cancer control annually and the numbers continue to grow. The oncology market is expected to increase in overall size and in the variety of available therapies, driven by the emergence of innovative drugs such as growth inhibitors, antisense, gene therapies, antisense and antiangiogenesis agents. The oncology market experienced substantial expansion during 2001, with a host of new products in development; the market grew by 11% in 2001 to US$12bn (IMS Health MAT).

Despite important advances in understanding the molecular basis of cancer, few treatments have been devised to specifically target the known defects in tumor cells. Standard chemotherapy or radiation treatments are inherently non-selective and kill normal cells along with malignant ones. Effective future treatments depend of developing drugs that target individual abnormalities in specific tumor cells. Specially promising new drug classes under development for treatment of cancer include monoclonal antibodies and
angiogenesis inhibitors.

This highlight report will provide you with an update on the most recent advances and the ongoing struggle for improved anti-angiogenesis and vascular targeting cancer therapeutics, with a central of attention on achievements and pitfalls that have been experienced. We outline the different strategies that today are believed to be necessary in order to achieve maximum clinical efficacy of the anticancer angiogenesis inhibitors.

This report highlights the areas regarded as the "hottest leads" at the moment. The main focuses include vascular endothelial growth factor and epidermal growth factor and their respective receptors, which are in Phase II to III trials. Followed by agents that target matrix metalloproteinases and integrins. A special interest is also given to the new vascular-targeting agents, which aim to disrupt existing tumor endothelium, and Cyclooxygenase-2 inhibitors that have been found to play a role in tumor angiogenesis. Further, we look at the specific therapeutic strategies adopted, namely small molecular drugs, monoclonal antibodies, endogenous inhibitors and antisense therapy.

Our Highlight Reports are produced to update our customers on the progress within different sectors of the pharmaceutical and biotechnology industry, and to define the most significant achievements and novel breakthroughs occurring during the latest years of activities. Apart from the pharma industry itself, this report is of value to investors, science incubators, investigators, contract research organizations or any other type of organization with an interest in anti-angiogenesis related to cancer.

For a complete index of this report click on
http://www.researchandmarkets.com/reports/39360

About Research and Markets Ltd.Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products
and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or
mailto:press@researchandmarkets.com
###